These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36064096)

  • 41. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
    Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
    Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
    Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
    World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence, management, and course of cancer in patients with inflammatory bowel disease.
    Algaba A; Guerra I; Marín-Jiménez I; Quintanilla E; López-Serrano P; García-Sánchez MC; Casis B; Taxonera C; Moral I; Chaparro M; Martín-Rodríguez D; Martín-Arranz MD; Manceñido N; Menchén L; López-Sanromán A; Castaño Á; Bermejo F
    J Crohns Colitis; 2015 Apr; 9(4):326-33. PubMed ID: 25687203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRN.
    Atia O; Harel S; Ledderman N; Greenfeld S; Kariv R; Dotan I; Balicer R; Silverman B; Matz E; Levi Z; Waterman M; Fried I; Rowe JM; Turner D
    J Crohns Colitis; 2022 Jun; 16(5):786-795. PubMed ID: 34791097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Table: safety of drugs for IBD in pregnancy.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e116. PubMed ID: 30036355
    [No Abstract]   [Full Text] [Related]  

  • 46. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients.
    de Jong ME; Smits LJT; van Ruijven B; den Broeder N; Russel MGVM; Römkens TEH; West RL; Jansen JM; Hoentjen F
    J Crohns Colitis; 2020 Jul; 14(7):888-895. PubMed ID: 31974546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.
    Deepak P; Stobaugh DJ
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1035-43. PubMed ID: 25164260
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
    Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
    J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?
    Maldonado-Pérez MB; Castro-Laria L; Caunedo-Álvarez A; Montoya-García MJ; Giner-García M; Argüelles-Arias F; Romero-Gómez M; Vázquez-Gámez MÁ
    J Clin Densitom; 2019; 22(2):195-202. PubMed ID: 30205986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?
    Lakatos PL; Miheller P
    Curr Drug Targets; 2010 Feb; 11(2):179-86. PubMed ID: 20210767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial.
    Meyer A; Neumann A; Drouin J; Weill A; Carbonnel F; Dray-Spira R
    Ann Intern Med; 2022 Oct; 175(10):1374-1382. PubMed ID: 36162111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study.
    Poullenot F; Amiot A; Nachury M; Viennot S; Altwegg R; Bouhnik Y; Abitbol V; Nancey S; Vuitton L; Peyrin-Biroulet L; Biron A; Fumery M; Picon L; Vidon M; Reenaers C; Serrero M; Savoye G; Beaugerie L; Rivière P; Laharie D
    J Crohns Colitis; 2022 Nov; 16(10):1523-1530. PubMed ID: 35512337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of Myeloid Neoplasms in Inflammatory Bowel Disease Patients Is Linked to Exposure to Thiopurines and Not With Tumor Necrosis Factor-alpha Inhibitors.
    Deepak P; Stobaugh DJ
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1857-8. PubMed ID: 25158928
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease.
    Lobatón T; Ferrante M; Rutgeerts P; Ballet V; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2015 Aug; 42(4):441-51. PubMed ID: 26104047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review.
    Muller M; D'Amico F; Bonovas S; Danese S; Peyrin-Biroulet L
    J Crohns Colitis; 2021 May; 15(5):840-859. PubMed ID: 32915970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
    Anjie SI; Hanzel J; Gecse KB; D'Haens GR; Brandse JF
    Scand J Gastroenterol; 2024; 59(2):169-175. PubMed ID: 37961895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study.
    Desai RJ; Gagne JJ; Lii J; Liu J; Friedman S; Kim SC
    CMAJ; 2017 Nov; 189(47):E1438-E1447. PubMed ID: 29180383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.
    Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Churchill S; Karlson EW; Murphy SN; Kohane I; Liao KP
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1141-8. PubMed ID: 25864945
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.
    Julsgaard M; Hvas CL; Gearry RB; Gibson PR; Fallingborg J; Sparrow MP; Bibby BM; Connell WR; Brown SJ; Kamm MA; Lawrance IC; Vestergaard T; Svenningsen L; Baekdal M; Kammerlander H; Walsh A; Boysen T; Bampton P; Radford-Smith G; Kjeldsen J; Andrews JM; Subramaniam K; Moore GT; Jensen NM; Connor SJ; Wildt S; Wilson B; Ellard K; Christensen LA; Bell SJ
    Inflamm Bowel Dis; 2020 Jan; 26(1):93-102. PubMed ID: 31141607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.